Squamous cell carcinomas and our anti-TMTC3 antibody

Article: "A Novel ER Stress Mediator TMTC3 Promotes Squamous Cell Carcinoma Progression by Activating GRP78/PERK Signaling Pathway"

The image, from Hongyu Yuan et al. (2022), shows the ectopic expression of TMTC3 in SCC tissues:
A. Representative IHC images of TMTC3 in the esophageal squamous cell carcinomas tissue array.
B. IHC staining score for each ESCC tissue spot was calculated based on the intensity and area of the staining for TMTC3.
C. High expression of TMTC3 was associated with poor survival in ESCC patients.

Squamous cell carcinomas show a specific expression pattern of TMTC3. Moreover, high expressions of TMTC3 are associated with poor survival in esophageal squamous cell carcinomas patients.

Squamous cell carcinomas (SCCs) are malignant tumors originating from epithelial organs, such as skin, esophagus, head and neck, lungs, and cervix. Although sourced from different tissues, SCCs maintain similar features, including genomic profiling, histological features, and molecular characteristics.

Our polyclonal anti-TMTC3 antibody (HPA038550) was used in a study published in "International Journal of Biological Sciences" by Hongyu Yuan et al. (2022) from the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

The study aimed to understand the role of TMTC3 (transmembrane and tetratricopeptide repeat containing 3) in promoting the oncogenic phenotype in esophageal squamous cell carcinomas (ESCC).

A specific expression pattern was observed for TMTC3 in squamous cell carcinomas. Moreover, high expressions of TMTC3 were associated with poor survival in ESCC patients.

Read full article here.

Find out more about our polyclonal anti-TMTC3 antibody (HPA038550).